IC

ICAD IncNASDAQ ICAD Stock Report

Last reporting period 30 Sep, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.041

Micro

Exchange

XNAS - Nasdaq

ICAD Stock Analysis

IC

Uncovered

ICAD Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

33/100

Low score

Market cap $B

0.041

Dividend yield

Shares outstanding

25.446 B

iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

View Section: Eyestock Rating